Education and Training
A Study of IMMray™ PanCan-d Test for Early Detection of Pancreatic Cancer in High-risk Groups
PanFAM-1 is a clinical study for early detection of pancreatic cancer in high-risk groups. The goals of the study are to assess the performance and diagnostic accuracy of the IMMray™ PanCan-d test compared to standard-of-care imaging.
Stanford is currently not accepting patients for this trial.
Eligibility
Inclusion Criteria:
1. Ability to understand and the willingness to sign a written informed consent document
2. Individuals with the following family phenotype and age:
1. Two or more relatives with pancreatic adenocarcinomas (PDAC) on the same side of
the family, where two PDAC-affected individuals are first degree related (FDR) +
at least one PDAC-affected individual is a FDR of the Participant (≥50 years old
OR 10 years before onset in family)
2. Two affected FDR with PDAC (≥50 years old OR 10 years before onset of an FDR)
3. Any of BRCA1, BRCA2, PALB2, ATM mutations confirmed pathogenic or likely
pathogenic + one FDR or secondary degree related (SDR) with PDAC (≥50 years old
OR 10 years before onset of an FDR and SDR)
4. Familial atypical multiple mole-melanoma (FAMMM) with confirmed pathogenic or
likely pathogenic mutation variants in: p16, CDKN2A (≥50 years old)
5. Known mutation carrier for STK11 (Peutz Jeghers Syndrome) (≥35 years old)
6. Lynch syndrome (HNPCC) with confirmed pathogenic or likely pathogenic variants
in: MLH1, MSH2, MSH6, PMS2, or EPCAM + one FDR or SDR with PDAC (≥50 years old OR
10 years before onset of an FDR or SDR)
7. Hereditary pancreatitis with confirmed PRSS1 pathogenic or likely pathogenic
history of pancreatitis (≥40 years old)
Exclusion Criteria:
None
Ages Eligible for Study
N/A - N/A
Genders Eligible for Study
All
Not currently accepting new patients for this trial
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Kellie Baumann
650) 725-3370
Not Recruiting